Trials / No Longer Available
No Longer AvailableNCT04518644
Nilotinib, for Patients With CML-CP or CML-AP
Managed Access Program to Provide Access to Nilotinib, for Patients With Imatinib-intolerant and/or Resistant Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase or CML in Accelerated Phase
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Cohort Treatment Plan is to allow access to Nilotinib for eligible patients diagnosed with imatinib-intolerant and/or resistant Philadelphia Chromosome positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) or Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nilotinib | The recommended dosing of nilotinib is 400 mg orally twice daily |
Timeline
- First posted
- 2020-08-19
- Last updated
- 2023-04-28
Source: ClinicalTrials.gov record NCT04518644. Inclusion in this directory is not an endorsement.